佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月26日南向资金增持35.7万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金增 持的有4天，累计净增持278.46万股。近20个交易日中，获南向资金增持的有11天，累计净增持720.84万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7570.44万股，占公司已发行普通股的5.73%。 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月23日南向资金增持196.32万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持87.0万股。近20个交易日中，获南向资金增持的有11天，累计净增持727.56万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7534.74万股，占公司已发行普通股的5.71%。 ...

证券之星消息，2月11日南向资金减持155.76万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持77.58万股。近20个交易日中，获南向资金增持的有11天，累计净增持690.0万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7291.98万股，占公司已发行普通股的5.52%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-02 | 7149.78万 | -3.78万 | -0.05% | | 2026-01-30 | 7153.56万 | -19.02万 | -0.27% | | 2026-01-29 | 7172.58万 | 2.04万 | 0.03% | | 2026-01-28 | 7170.54万 | 22.02万 | 0.31% | | 2026-01-27 | 7148.52万 | -64.80万 | -0.90% | 证券之星消息，2月2日南向资金减持3.78万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有3天，累计净减持63.54万股。近20个交易日中，获南向资金增持的有13天，累计净增持834.6万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7149.78万股，占公司已发行普通股的5.41%。 佰泽医疗集团是一家 ...

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Baize Medical (02609.HK), indicating a reduction of 369,000 shares on January 8, while showing a net increase of 4,179,000 shares over the past five trading days [1] - Over the last 20 trading days, Baize Medical experienced a net increase of 2,540,400 shares from southbound funds, with 11 days of net buying [1] - As of now, southbound funds hold 65,397,000 shares of Baize Medical, representing 4.96% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Group 1 - Southbound funds increased their holdings in Baize Medical (02609.HK) by 1.8354 million shares on December 22 [1] - Over the past 5 trading days, there have been 4 days of net increases in holdings by southbound funds, totaling 4.0362 million shares [1] - In the last 20 trading days, there were 9 days of net increases, amounting to 534,600 shares [1] Group 2 - As of now, southbound funds hold 6.45108 million shares of Baize Medical, representing 4.89% of the company's total issued ordinary shares [1] - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1]

Core Viewpoint - Southbound funds increased their holdings in Baize Medical (02609.HK) by 10,200 shares on December 9, indicating a potential positive sentiment towards the company [1] Group 1: Southbound Fund Activity - Over the past 5 trading days, there was a net reduction of 382,800 shares, with southbound funds reducing their holdings on one day [1] - In the last 20 trading days, there were 10 days of net reductions totaling 2,009,400 shares [1] - Currently, southbound funds hold 62,471,400 shares of Baize Medical, representing 4.73% of the company's total issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations, primarily in the Chinese market [1]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 103,200 shares on November 20, 2025, indicating a potential positive sentiment towards the company in the market [1]. Summary by Sections Southbound Fund Activity - In the last five trading days, southbound funds have increased their holdings for three days, with a total net increase of 58,200 shares [1]. - Over the past 20 trading days, there have been 12 days of net reductions, totaling 1,262,400 shares [1]. - As of now, southbound funds hold 63,604,200 shares of Baize Medical, accounting for 4.81% of the company's total issued ordinary shares [1]. Shareholding Changes - On November 20, 2025, the total number of shares held was 63,604,200, with a change of 103,200 shares, reflecting a 0.16% increase [2]. - On November 19, 2025, the total was 63,501,000 shares, with a decrease of 150,600 shares, showing a -0.24% change [2]. - On November 18, 2025, the total was 63,651,600 shares, with an increase of 176,400 shares, indicating a 0.28% rise [2]. - On November 17, 2025, the total was 63,475,200 shares, with a decrease of 152,400 shares, reflecting a -0.24% change [2]. - On November 14, 2025, the total was 63,627,600 shares, with an increase of 81,600 shares, showing a 0.13% rise [2]. Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2]. - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2]. - Its business encompasses hospital operations, management services, supply of pharmaceuticals, medical devices, consumables, and other related services [2]. - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations, primarily operating in the Chinese market [2].

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 1.62% on October 27, 2025, amounting to a decrease of 106.2 million shares [1][2] - Over the past five trading days, southbound funds have reduced their holdings for four days, with a total net reduction of 257.4 million shares [1][2] - As of now, southbound funds hold 64.476 million shares of Baize Medical, representing 4.88% of the company's total issued ordinary shares [1][2] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Its business operations include hospital services, hospital management services, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2]

Core Insights - Southbound funds reduced their holdings in Baize Medical (02609.HK) by 1.7418 million shares on October 22, 2025, marking a decrease of 2.61% [1][2] - Over the past five trading days, there were four days of reductions, totaling a net decrease of 2.274 million shares [1] - In the last twenty trading days, southbound funds increased their holdings on twelve occasions, with a cumulative net increase of 45.6066 million shares [1] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [2] - The company conducts cancer diagnosis, treatment, rehabilitation, and end-of-life care for patients, as well as early cancer screening, cancer vaccination, and health management services for other potential health populations [2] - Baize Medical primarily operates in the Chinese market [2]